Clinical trials: sponsored by The Methodist Hospital Research Institute
Non-Hodgkin Lymphoma
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study
The purpose of this study is to determine the rate of response to the drugs bortezomib (Velcade) and vorinostat (Zolinza), when used in combination, in patients with relapsed (recurrent) and/or refractory (difficult to treat)…
- Trial name
- COMBOSTAT (NCT00837174)
- Testing
- Vorinostat in combination with Bortezomib
- Sponsor
- The Methodist Hospital Research Institute
Central Nervous System (CNS) Metastases, Brain Metastases
Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors
The specific purpose of this study is to obtain data on safety and efficacy of combination chemotherapy with Temozolomide and Topotecan in patients with CNS metastases of solid tumors.
- Trial name
- NCT01736800
- Testing
- Topotecan, Temozolomide
- Where
- 2 sites in United States
- Sponsor
- The Methodist Hospital Research Institute
Spinal Cord Injury
Safety of Riluzole in Patients With Acute Spinal Cord Injury
The purpose of the study is to find out if the use of the drug Riluzole is both safe and improves outcome in patients with acute traumatic spinal cord injury (SCI).
- Trial name
- NCT00876889
- Testing
- Riluzole
- Where
- 8 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- The Methodist Hospital Research Institute
Prostatic Neoplasms
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
The purpose of this study is to conduct a Phase I - II clinical trial to extend preclinical studies involving in situ HSV-tk + Valacyclovir gene therapy in combination with brachytherapy for recurrent prostate cancer.
- Trial name
- NCT01913106
- Testing
- HSV-tk +Valacyclovir in Combination with Brachytherapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- The Methodist Hospital Research Institute
Carcinoma, Renal Cell
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
The purpose of this study is to see whether the combination for RAD001 and Nexavar® works better when given together than they do alone.
- Trial name
- NCT00448149
- Testing
- RAD001, Sorafenib
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- The Methodist Hospital Research Institute
Carcinoma, Renal Cell
Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer
Patients with metastatic renal cell cancer will be enrolled to receive RAD001 to determine whether the use of RAD001 will result in an improvement in the time to tumor progression.
- Trial name
- RAD001 (NCT00446368)
- Testing
- RAD001
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- The Methodist Hospital Research Institute
Prostatic Neoplasms
Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer
The purpose of this study is to evaluate the role of combination therapy with Trovax plus Docetaxel or Docetaxel alone in patients with prostate cancer with a rising prostate specific antigen (PSA).
- Trial name
- NCT00521274
- Testing
- MVA 5T4, Docetaxel
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- The Methodist Hospital Research Institute
Carcinoma, Renal Cell
Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer
Patients with metastatic renal cell cancer will be enrolled to receive either Trovax® alone or Trovax® plus Interferon Alfa. The study will try to determine whether the use of Trovax® will delay tumor progression.
- Trial name
- NCT00445523
- Testing
- TroVax® (Immunological Vaccine Therapy), Interferon-alpha
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The Methodist Hospital Research Institute
Carcinoma, Renal Cell
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
The purpose of this study is to determine the safety and toxicity levels of Dose Escalated Sorafenib in the treatment of patients with renal cancer.
- Trial name
- NCT00445042
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- The Methodist Hospital Research Institute
Prostatic Neoplasms
Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer
The purpose of this study is to assess the relative efficacy and toxicity of combination therapy of GM-CSF, Thalidomide plus Docetaxel in patients with prostate cancer with a rising PSA.
- Trial name
- NCT00450008
- Testing
- GM-CSF, thalidomide, docetaxel
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The Methodist Hospital Research Institute
Prostatic Neoplasms
Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer
The purpose of the clinical trial is to assess the clinical benefit as measured by time to tumor progression of Abraxane plus hormonal therapy when applied to previously untreated patients with unresectable or metastatic…
- Trial name
- NCT00521781
- Testing
- Abraxane, Leuprolide, Bicalutamide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- The Methodist Hospital Research Institute
Prostatic Neoplasms
Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
To evaluate the efficacy and safety of Trovax and GM-CSF in patients with prostate cancer.
- Trial name
- NCT00448409
- Testing
- TroVax, GM-CSF
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- The Methodist Hospital Research Institute
Esophageal or Gastric Perforations, Esophageal or Gastric Leaks
A Trial of Esophageal and Gastric Stenting for Leak or Perforation
Long term follow-up of patients treated for esophageal fistulas with a newer occlusive self-expanding covered metal stents compared to traditional stents.
- Trial name
- ESO-stent (NCT01107249)
- Testing
- Boston Scientific Ultraflex or Wallstent stents
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The Methodist Hospital Research Institute
Carcinoma, Renal Cell
Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer
The purpose of this study is to determine if the combination of therapy to strengthen the immune system (Interleukin - 2) plus a specific tumor target therapy (Bevacizumab) can prolong the time between the start of treatment and…
- Trial name
- NCT00440973
- Testing
- Bevacizumab, Interleukin-2
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- The Methodist Hospital Research Institute
Prostatic Neoplasms
Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy
The purpose of this study is to differentiate between the administrations of Cetuximab alone vs. Cetuximab plus Docetaxel in the treatment of non-metastatic prostate cancer before the surgical removal of the prostate.
- Trial name
- NCT00448097
- Testing
- cetuximab, docetaxel
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- The Methodist Hospital Research Institute
Prostatic Neoplasms
Efficacy and Safety Study of Xyotax to Treat Prostate Cancer
The purpose of this study is to determine whether Xyotax, a conjugate of the taxane drug paclitaxel, is effective in the treatment of prostate cancer that is no longer responsive to hormone therapy.
- Trial name
- NCT00446836
- Testing
- Paclitaxel polyglumex (Xyotax)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- The Methodist Hospital Research Institute
Carcinoma, Renal Cell
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
The purpose of this study is to evaluate the combination of Pegylated Alfa Interferon (PEG-Intron), Sunitinib and Tarceva to see if this drug combination delays the disease progression of patients with metastatic Renal Cell…
- Trial name
- NCT00522249
- Testing
- Pegylated Alfa Interferon, sunitinib, erlotinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The Methodist Hospital Research Institute
Prostatic Neoplasms
Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer
This trial represents an attempt to offer second line immunotherapy plus chemotherapy to patients who have failed prior taxane base therapy.
- Trial name
- NCT00447473
- Testing
- GM-CSF, Ketoconazole, Mitoxantrone
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- The Methodist Hospital Research Institute
Amyotrophic Lateral Sclerosis
Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis
The role of hyperlipidemia and lipid lowering therapy (LLT) in Amyotrophic Lateral Sclerosis (ALS) pathophysiology and its impact on disease progression and survival is unclear.
- Trial name
- NCT01592084
- Where
- United States
- Volunteers
- 267 people
- Sponsor
- The Methodist Hospital Research Institute
Septic Shock, Acute Adrenal Insufficiency
Adrenal Insufficiency in Septic Shock
Randomized controlled trial evaluating the duration of steroid replacement therapy in patients with adrenal insufficiency and septic shock.
- Trial name
- NCT00842933
- Testing
- Corticosteroid
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- The Methodist Hospital Research Institute